About PROGRAF
PROGRAF is a Healthcare company. It operates as an immunosuppressant medication for preventing organ rejection in transplant patients. PROGRAF offers products and services including PROGRAF Capsules and PROGRAF Granules. Its focus areas include Pharmaceuticals, Immunosuppressants, Organ Transplant Drugs and Medical Services. Its legal entity is Astellas Pharma US, Inc.
Company details
PROGRAF, a tacrolimus-based prescription drug, is employed with other medicines to prevent organ rejection following kidney, liver, heart, or lung transplants, and it is available as immediate-release capsules or granules for specific patient needs. Immediate-release forms are distinguished from extended-release versions, with decisions on usage made by healthcare providers. Safety concerns include risks of cancer and infections, which must be monitored, along with interactions with other drugs. Patient support resources are offered to assist in post-transplant care, ensuring that information is shared responsibly.
- SectorsHealthcare
- Legal Name Astellas Pharma Us, Inc
Products & Services of PROGRAF
PROGRAF offers a comprehensive portfolio of products and services, including PROGRAF Capsules and PROGRAF Granules.
Tacrolimus immediate-release capsules are utilized to prevent organ rejection in transplant patients
Tacrolimus immediate-release granules are provided as an oral suspension for children who experience difficulties with swallowing capsules
Web traffic of PROGRAF
Websites that share an audience with PROGRAF (prograf.com).
Websites whose visitors overlap most with PROGRAF. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| larenon.com | 100% | 12.7K | #1,761,991 | View details | |
| proleukin.com | 90% | 1.2K | #8,599,991 | View details |
Top companies in Transplant Medicine
10 companies that operate in the same segment as PROGRAF (Transplant Medicine), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical solutions for transplant patients are developed and provided. | 1998 | Brisbane, California, United States | USD 138.21 M | USD 379.81 M | 650 | |
Developer of organ transplantation technology | 1998 | Andover, Massachusetts, United States | USD 265.55 M | USD 605.49 M | 728 | |
Warm storage and transport systems for harvested organs are provided. | 2008 | Oxford, Oxfordshire, United Kingdom | USD 45.42 M | USD 1.36 M | 14 | |
Human tissue-based products are developed for vascular disease applications. | 2004 | Morrisville, United States | USD 424.76 M | USD 2.04 M | 220 | |
Next-generation medicines for CNS and immunological disorders are developed. | 2007 | New York, New York, United States | USD 4.45 M | USD 13.11 M | 81 | |
Breakthrough therapies are developed for blood diseases and infections. | 2014 | Buffalo, New York, United States | USD 1 M | – | 22 | |
Personalized skin tissue therapy is developed by CUTISS for surgeries. | 2017 | Zurich, Switzerland | USD 94.37 M | – | – | |
Game currency trading services are provided by Magenta Piman. | 2016 | Cambridge, Massachusetts, United States | USD 150.5 M | – | 75 | |
T regulatory cell therapies are developed for immunological diseases. | 2019 | London, England, United Kingdom | USD 344.25 M | – | – | |
Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed. | 2004 | Irvine, California, United States | USD 1.89 M | – | 31 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PROGRAF
PROGRAF, a tacrolimus-based prescription drug, is employed with other medicines to prevent organ rejection following kidney, liver, heart, or lung transplants, and it is available as immediate-release capsules or granules for specific patient needs. Immediate-release forms are distinguished from extended-release versions, with decisions on usage made by healthcare providers. Safety concerns include risks of cancer and infections, which must be monitored, along with interactions with other drugs. Patient support resources are offered to assist in post-transplant care, ensuring that information is shared responsibly.
PROGRAF offers PROGRAF Capsules and PROGRAF Granules.
PROGRAF operates through Astellas Pharma Us, Inc.